Tonix Pharmaceuticals Holding Corp. (TNXP): Price and Financial Metrics
TNXP Price/Volume Stats
| Current price | $0.14 | 52-week high | $3.34 |
| Prev. close | $0.15 | 52-week low | $0.12 |
| Day low | $0.12 | Volume | 4,197,385 |
| Day high | $0.15 | Avg. volume | 2,186,313 |
| 50-day MA | $0.31 | Dividend yield | N/A |
| 200-day MA | $0.64 | Market Cap | 11.52M |
TNXP Stock Price Chart Interactive Chart >
Tonix Pharmaceuticals Holding Corp. (TNXP) Company Bio
Tonix Pharmaceuticals Holding Corp. is a pharmaceutical company that develops therapies for disorders of the central nervous system ("CNS"). The Company develops therapies for disorders that include fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD").
Latest TNXP News From Around the Web
Below are the latest news stories about TONIX PHARMACEUTICALS HOLDING CORP that investors may wish to consider to help them evaluate TNXP as an investment opportunity.
Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 MillionLed by healthcare-focused institutional investors. $30 million financing upfront with up to an additional $114 million tied to the exercise of warrants. CHATHAM, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company has signed securities purchase agreements with certain healthcare-focused institutional investors that have agreed to pr |
Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of FibromyalgiaFigure 1 Pain Reduction Over Course of Study Phase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint, p = 0.00005) All six key secondary endpoints, including patient global impression, fibromyalgia-specific symptoms and dysfunction, fatigue and sleep measures were significantly improved (all p ≤ 0.001) Positive results support planned New Drug Application (NDA) submission to the FDA in the second half of 2024An estimated 6 million to 1 |
Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SLTopline Data from a Registration-Enabling Phase 3 Clinical Trial is Due Later This Month.CHATHAM, NJ / ACCESSWIRE / December 14, 2023 / Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, sleep problems and brain fog. It ... |
Tonix Pharmaceuticals shared details of IND clearance for Phase 2 trial of TNX-2900Tonix Pharmaceuticals CEO Dr Seth Lederman joined Steve Darling from Proactive to delve into the significant development involving the US Food and Drug Administration (FDA)'s clearance of the Inves... |
Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public MeetingCHATHAM, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the National Academies of Sciences, Engineering, and Medicine Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures public meeting on Thursday, |
TNXP Price Returns
| 1-mo | -56.39% |
| 3-mo | -50.89% |
| 6-mo | -74.55% |
| 1-year | -95.62% |
| 3-year | -99.93% |
| 5-year | -100.00% |
| YTD | -65.26% |
| 2023 | -83.46% |
| 2022 | -96.59% |
| 2021 | -47.01% |
| 2020 | -42.31% |
| 2019 | -94.68% |
Loading social stream, please wait...